Literature DB >> 24048350

The half-cycle correction revisited: redemption of a kludge.

David M J Naimark1,2, Nader N Kabboul2, Murray D Krahn1.   

Abstract

Decision-analytic software commonly used to implement discrete Markov models requires transitions to occur between simulated health states either at the beginning or at the end of each cycle. The result is an over- or underestimation, respectively, of quality-adjusted life expectancy and cost, compared with the results that would be obtained if transitions were modeled to occur randomly throughout each cycle. The standard half-cycle correction (HCC) is used to remedy the bias. However, the standard approach to the HCC is problematic: It does not account for discounting or for the shape of intermediate state membership functions. Application of the standard approach to the HCC also has no numerical effect on the resulting incremental cost-effectiveness ratio or change in net health benefit under certain circumstances. Alternatives to the standard HCC, in order of ease of use, include no correction, the life-table approach, the cycle-tree method, and a correction based on Simpson's rule. For less complex decision models in which the computational burden is not large, reducing the cycle length to a month or less and using no correction should result in small estimation biases. With more complex models, where cycle lengths larger than 1 month may be necessary to make computation feasible, we recommend the cycle tree approach. The latter is relatively easy to apply and has an intuitive appeal: Hypothetical subjects who transition from one state to another, on average halfway through a cycle, should receive half of the value associated with the state from which they come and half the value of the state to which they are going.

Keywords:  Markov models; discrete state transition models; half-cycle correction

Mesh:

Year:  2013        PMID: 24048350     DOI: 10.1177/0272989X13501558

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  11 in total

1.  Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers.

Authors:  Elamin H Elbasha; Jagpreet Chhatwal
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.

Authors:  Ian Cromwell; Dean A Regier; Stuart J Peacock; Catherine F Poh
Journal:  Oncologist       Date:  2016-07-11

3.  Cost-Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario.

Authors:  Kyle P Fitzgibbon; Donna Plett; Brian C F Chan; Rebecca Hancock-Howard; Peter C Coyte; Daniel M Blumberger
Journal:  Can J Psychiatry       Date:  2019-12-05       Impact factor: 4.356

4.  Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.

Authors:  James F O'Mahony; Anthony T Newall; Joost van Rosmalen
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

5.  Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Authors:  Lauren Lapointe-Shaw; Kim L Tran; Peter C Coyte; Rebecca L Hancock-Howard; Jeff Powis; Susan M Poutanen; Susy Hota
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

6.  Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.

Authors:  Rashidah T Uthman; Andrew J Sutton; Louise J Jackson; Olalekan A Uthman
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

7.  Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Authors:  Erin Johansson; Mercedes Nuñez; Axel Svedbom; Tatiana Dilla; Susanne Hartz
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-12

8.  A theoretical foundation for state-transition cohort models in health decision analysis.

Authors:  Rowan Iskandar
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

9.  Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease.

Authors:  Austin Nam; David M J Naimark; Matthew B Stanbrook; Murray D Krahn
Journal:  MDM Policy Pract       Date:  2019-05-27

10.  Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting.

Authors:  Tristan M Snowsill; Neil A J Ryan; Emma J Crosbie; Ian M Frayling; D Gareth Evans; Chris J Hyde
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.